September 12, 2022
Article
With encouraging overall response and disease control rates, lenvatinib plus pembrolizumab has the potential to be a frontline treatment option for non–clear cell renal cell carcinoma.
June 04, 2022
Article
According to new COSMIC-021 data, atezolizumab combined with cabozantinib may be active in patients with urothelial carcinoma.
June 10, 2021
Article
In patients with muscle-invasive bladder cancer treated in the phase 2 HCRN GU16-257 trial, the combination of transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise.
June 03, 2021
Article
LuPSMA added to standard of care led to a nearly 40% reduction in the risk of death versus standard of care alone in the phase 3 VISION study.
May 19, 2021
Article
Improved outcomes for younger African American patients is associated with increased prostate-specific antigen screening.
February 13, 2021
Article
Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.